Nearly two-thirds of the members of the panel are outspoken opponents of fetal tissue research
THURSDAY, Aug. 20, 2020 (HealthDay News) — A Trump administration advisory board to evaluate scientific research involving fetal tissue says 13 of 14 proposals should be rejected.
The board, created in February, issued a report Tuesday about its recommendation. Health Secretary Alex Azar will make the final decision, but the 15-member panel is expected to have considerable influence, according to The New York Times.
Nearly two-thirds of the members of the panel are outspoken opponents of the fetal tissue research, and supporters of such research say its opinions are tainted.
“The evaluation process for research should be insulated from ideology and special interests,” the International Society for Stem Cell Research said in a statement, The Times reported. “It is disheartening to see an ethics review perverted by an administration seeking to achieve a policy goal, a near ban on research with human fetal tissue.”
Stem Cell Treatment Feasible for Aniridia-Related Keratopathy 
Patient Education Increases Skin Cancer Screening in Stem Cell Transplant Survivors 
Indefinite-Duration Maintenance Therapy No Better Than Fixed-Duration Therapy in Multiple Myeloma 
Definition of Functional High-Risk Multiple Myeloma Updated in Era of Combo Therapy 
Azacitidine + Venetoclax Tied to Improved Event-Free Survival in Adults With AML 
Dexrazoxane Offers Lasting Doxorubicin Cardioprotective Effect in Childhood Cancer Survivors 
Enfortumab Vedotin-Pembrolizumab More Effective for MIBC Than Cisplatin-Gemcitabine 
Pembrolizumab-Belzutifan Tied to Improved Disease-Free Survival in Renal Cell Carcinoma 
